MALIGNANT SOLID TUMOR
Clinical trials for MALIGNANT SOLID TUMOR explained in plain language.
Never miss a new study
Get alerted when new MALIGNANT SOLID TUMOR trials appear
Sign up with your email to follow new studies for MALIGNANT SOLID TUMOR, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection tackles Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumors to see if it is safe and tolerable. About 97 adults with various solid cancers…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated May 16, 2026 22:31 UTC
-
New study matches cancer drugs to tumor DNA
Disease control Recruiting nowThis study tests cancer treatments that target specific genetic changes in tumors. It is for people with advanced solid tumors that have not responded to standard therapies. Participants receive a treatment chosen based on their tumor's molecular profile. The goal is to see if th…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated May 16, 2026 22:26 UTC
-
New hope for advanced cancer: FH-006 trial begins
Disease control Recruiting nowThis study tests a new drug called FH-006 in 200 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if it can shrink tumors. Participants will be closely monitored for side effects and how their body proce…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug cocktail shows promise for kids with rare cancers
Disease control Recruiting nowThis study tests a combination of four drugs (cyclophosphamide, sorafenib, bevacizumab, and atezolizumab) in children and young adults with solid tumors that have come back or not responded to treatment. The goal is to find safe doses and see if the drugs shrink tumors. The trial…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for Hard-to-Treat cancers: first human trial begins
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. It is the first time this drug is being used in humans. The study has two parts: first, to find the safest dose, and second, to see how well…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New PET tracer could reveal if immunotherapy is working
Diagnosis Recruiting nowThis study is testing a new imaging agent (GEH200520/GEH200521) that uses a PET scan to take pictures of solid tumors. In the first part, researchers check the safety of the agent in 50 adults with advanced cancer. In the second part, they use the agent to see if tumors change af…
Matched conditions: MALIGNANT SOLID TUMOR
Phase: PHASE1 • Sponsor: GE Healthcare • Aim: Diagnosis
Last updated May 12, 2026 13:40 UTC
-
Massive canadian study hunts rare cancer clues
Knowledge-focused Recruiting nowThis study follows 5,500 Canadian cancer patients whose tumors have rare genetic changes. Researchers will collect data on how these cancers behave and how well different treatments work, including newer targeted drugs. The goal is to learn more about these uncommon mutations to …
Matched conditions: MALIGNANT SOLID TUMOR
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated May 13, 2026 15:59 UTC